Kubota Vision announced the publication of a new paper in the journal Scientific Reports: “Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans”.
Israel-based Belkin Vision announced that it has received CE Mark for its Eagle device, making it the first automated, non-contact glaucoma laser treatment available within Europe.
LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441 for its OcuRing Drug Delivery Platform.
Nicox SA revealed positive post-hoc data from its Mississippi Phase 2b clinical trial, finding that once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, is beneficial in alleviating dry eye symptoms in a subgroup of patients.
A revolutionary new treatment for cataracts has shown extremely positive results in laboratory tests, giving hope that the condition, which currently can only be cured with surgery, could soon be treated with drugs.
A novel combination of omega-3 and omega-6 fatty acids taken as a dietary supplement significantly improves symptoms in patients with severe dry eye disease, according to a new study conducted by the Centre for Ocular Research and Education (CORE).
A team of researchers working at Sun Yat-Sen University in China has developed a contact lens that can be used to monitor eye pressure changes and to administer glaucoma drugs when needed.
Kiora Pharmaceuticals revealed topline data from its vehicle-controlled, randomized safety study of KIO-101 eye drops.
Apellis Pharmaceuticals announced that the company has submitted a new drug application (NDA) to the FDA for intravitreal pegcetacoplan, an investigational, targeted C3 therapy, for the treatment of geographic atrophy (GA) secondary to AMD.
Nicox SA has received a formulation patent for NCX 470, its flagship pharmaceutical candidate in development for patients with open-angle glaucoma or ocular hypertension, from the Chinese National Intellectual Property Administration (CNIPA).
More